Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Goldman, Jonathan; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian; ÖZGÜROĞLU, Mustafa; Ji, Jun; Garassino, Marina; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libor; Bondarenko, Igor; Kazarnowicz, Andrzej; Losonczy, Gyorgy; Conev, Nikolay; Armstrong, Jon; Byrne, Natalie; Thiyagarajah, Piruntha; Jiang, Haiyi; Paz-Ares, Luis

doi:10.1016/s1470-2045(20)30539-8

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Copy For Citation

Goldman J. W., Dvorkin M., Chen Y., Reinmuth N., Hotta K., Trukhin D., ...More

LANCET ONCOLOGY, vol.22, no.1, pp.51-65, 2021 (SCI-Expanded)

Publication Type: Article / Article
Volume: 22 Issue: 1
Publication Date: 2021
Doi Number: 10.1016/s1470-2045(20)30539-8
Journal Name: LANCET ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE
Page Numbers: pp.51-65
Istanbul University Affiliated: No

Abstract

Background First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stage smallcell lung cancer (ES-SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide alone.